IDT Australia Director Increases Indirect Shareholding via On-Market Purchase

IDT Australia Limited ( (AU:IDT) ) has provided an update.

IDT Australia has disclosed a change in director Mark Simari’s interests, with an indirect on-market purchase of 501,936 ordinary fully paid shares at $0.048 per share. The transaction, executed via entities Charkaroo Pty Ltd and Jodmar Pty Ltd, lifts his indirect holding to 1,087,912 shares while maintaining 6,000,000 unlisted options and was carried out during a closed period under prior written clearance, signaling increased director alignment with shareholders.

The notified acquisition underscores board-level confidence in the company’s prospects, as a director increases his exposure to equity rather than reducing it. For investors and other stakeholders, such a move can be interpreted as a positive governance signal, though it does not in itself alter the company’s operations, strategy, or capital structure beyond the incremental change in market ownership.

The most recent analyst rating on (AU:IDT) stock is a Hold with a A$0.05 price target. To see the full list of analyst forecasts on IDT Australia Limited stock, see the AU:IDT Stock Forecast page.

More about IDT Australia Limited

IDT Australia Limited is an Australian pharmaceutical company listed on the ASX, focused on the development and manufacture of specialty medicines. The company operates in the healthcare and life sciences sector, with its securities actively traded on the Australian market as ordinary fully paid shares and various option classes.

Average Trading Volume: 195,291

Technical Sentiment Signal: Sell

Current Market Cap: A$22.21M

For an in-depth examination of IDT stock, go to TipRanks’ Overview page.